China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) — Stock Price
China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) is currently trading at CN¥16.40 CNY, up 0.24% today. Over the past 52 weeks, shares have ranged between CN¥15.60 and CN¥20.43. This page tracks China Resources Double-Crane Pharmaceutical Co Ltd's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 600062 stock market capitalisation.
China Resources Double-Crane Pharmaceutical Co Ltd (600062) Stock Price Chart — Daily History & Trading Volume
The chart below tracks China Resources Double-Crane Pharmaceutical Co Ltd's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
China Resources Double-Crane Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year
China Resources Double-Crane Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CN¥11.21 Billion | CN¥11.31 Billion | CN¥9.63 Billion | CN¥9.11 Billion | CN¥8.50 Billion |
| Cost of Revenue | CN¥4.83 Billion | CN¥4.90 Billion | CN¥4.31 Billion | CN¥4.05 Billion | CN¥3.16 Billion |
| Gross Profit | CN¥6.38 Billion | CN¥6.41 Billion | CN¥5.32 Billion | CN¥5.06 Billion | CN¥5.35 Billion |
| Research & Development | CN¥725.55 Million | CN¥627.85 Million | CN¥482.48 Million | CN¥409.59 Million | CN¥291.02 Million |
| SG&A | CN¥939.42 Million | CN¥861.58 Million | CN¥743.13 Million | CN¥692.53 Million | CN¥715.03 Million |
| Total Operating Expenses | CN¥4.55 Billion | CN¥4.53 Billion | CN¥3.89 Billion | CN¥3.93 Billion | CN¥4.12 Billion |
| Operating Income | CN¥1.83 Billion | CN¥1.88 Billion | CN¥1.43 Billion | CN¥1.14 Billion | CN¥1.23 Billion |
| EBITDA | CN¥2.36 Billion | CN¥2.39 Billion | CN¥1.78 Billion | CN¥1.48 Billion | CN¥1.55 Billion |
| EBIT | CN¥1.64 Billion | CN¥1.73 Billion | CN¥1.24 Billion | CN¥1.03 Billion | CN¥1.17 Billion |
| Interest Expense | CN¥16.77 Million | CN¥16.97 Million | CN¥11.95 Million | CN¥12.55 Million | CN¥4.21 Million |
| Income Before Tax | CN¥1.87 Billion | CN¥1.94 Billion | CN¥1.43 Billion | CN¥1.12 Billion | CN¥1.22 Billion |
| Income Tax Expense | CN¥215.94 Million | CN¥272.71 Million | CN¥201.27 Million | CN¥149.06 Million | CN¥201.52 Million |
| Net Income | CN¥1.63 Billion | CN¥1.67 Billion | CN¥1.18 Billion | CN¥935.69 Million | CN¥1.01 Billion |
China Resources Double-Crane Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes China Resources Double-Crane Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CN¥16.69 Billion | CN¥15.43 Billion | CN¥14.48 Billion | CN¥13.68 Billion | CN¥12.42 Billion |
| Total Current Assets | CN¥7.48 Billion | CN¥7.64 Billion | CN¥7.16 Billion | CN¥7.52 Billion | CN¥6.80 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | CN¥-4.88 Million | CN¥200.49 Million | CN¥803.58 Million | CN¥851.95 Million |
| Net Receivables | CN¥2.78 Billion | CN¥2.40 Billion | CN¥2.63 Billion | CN¥1.98 Billion | CN¥2.09 Billion |
| Inventory | CN¥1.59 Billion | CN¥1.56 Billion | CN¥1.88 Billion | CN¥1.67 Billion | CN¥1.29 Billion |
| Property, Plant & Equipment | — | — | — | CN¥2.96 Billion | CN¥2.67 Billion |
| Goodwill | CN¥878.49 Million | CN¥906.06 Million | CN¥934.96 Million | CN¥788.19 Million | CN¥796.41 Million |
| Total Liabilities | CN¥5.57 Billion | CN¥3.64 Billion | CN¥3.75 Billion | CN¥3.20 Billion | CN¥3.04 Billion |
| Total Current Liabilities | CN¥4.00 Billion | CN¥3.16 Billion | CN¥3.01 Billion | CN¥2.73 Billion | CN¥2.67 Billion |
| Long-term Debt | CN¥1.09 Billion | — | CN¥200.00 Million | — | — |
| Net Debt | CN¥-1.68 Billion | CN¥-3.40 Billion | CN¥-2.37 Billion | CN¥-2.77 Billion | CN¥-2.40 Billion |
| Total Stockholder Equity | CN¥10.41 Billion | CN¥11.09 Billion | CN¥10.02 Billion | CN¥9.91 Billion | CN¥9.29 Billion |
| Retained Earnings | CN¥9.24 Billion | CN¥10.01 Billion | CN¥8.56 Billion | CN¥8.20 Billion | CN¥7.58 Billion |
China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how China Resources Double-Crane Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥1.83 Billion | CN¥1.65 Billion | CN¥1.34 Billion | CN¥1.34 Billion | CN¥1.36 Billion |
| Capital Expenditures | CN¥637.50 Million | CN¥614.31 Million | CN¥525.53 Million | CN¥491.67 Million | CN¥348.09 Million |
| Free Cash Flow | CN¥1.19 Billion | CN¥1.03 Billion | CN¥816.14 Million | CN¥849.25 Million | CN¥1.01 Billion |
| Investing Cash Flow | CN¥982.46 Million | CN¥-707.76 Million | CN¥666.78 Million | CN¥-569.80 Million | CN¥-417.98 Million |
| Financing Cash Flow | CN¥-3.18 Billion | CN¥-358.32 Million | CN¥-1.29 Billion | CN¥-378.62 Million | CN¥-386.18 Million |
| Dividends Paid | CN¥1.48 Billion | CN¥300.48 Million | CN¥799.19 Million | CN¥302.54 Million | CN¥317.14 Million |
| Stock-Based Compensation | — | — | CN¥2.10 Million | — | — |
| Depreciation | CN¥756.29 Million | CN¥650.20 Million | CN¥540.58 Million | CN¥465.00 Million | CN¥371.71 Million |
| Change in Cash | CN¥-370.03 Million | CN¥588.38 Million | CN¥729.56 Million | CN¥393.80 Million | CN¥555.93 Million |
China Resources Double-Crane Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track China Resources Double-Crane Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 16, 2025 | — | — | — |
| Apr 27, 2023 | 0.36 | — | — |
| Mar 27, 2023 | 0.17 | — | — |
| Oct 25, 2022 | 0.23 | — | — |
| Aug 23, 2022 | 0.40 | — | — |
| Apr 28, 2022 | 0.32 | — | — |
| Mar 24, 2022 | 0.05 | — | — |
| Oct 29, 2021 | 0.28 | — | — |